These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 28323966)

  • 1. Persistent Reduction of Circulating Myeloid Calcifying Cells in Acromegaly: Relevance to the Bone-Vascular Axis.
    Fadini GP; Dassie F; Cappellari R; Persano M; Vigili de Kreutzenberg S; Martini C; Parolin M; Avogaro A; Vettor R; Maffei P
    J Clin Endocrinol Metab; 2017 Jun; 102(6):2044-2050. PubMed ID: 28323966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Widespread increase in myeloid calcifying cells contributes to ectopic vascular calcification in type 2 diabetes.
    Fadini GP; Albiero M; Menegazzo L; Boscaro E; Vigili de Kreutzenberg S; Agostini C; Cabrelle A; Binotto G; Rattazzi M; Bertacco E; Bertorelle R; Biasini L; Mion M; Plebani M; Ceolotto G; Angelini A; Castellani C; Menegolo M; Grego F; Dimmeler S; Seeger F; Zeiher A; Tiengo A; Avogaro A
    Circ Res; 2011 Apr; 108(9):1112-21. PubMed ID: 21393578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myeloid calcifying cells promote atherosclerotic calcification via paracrine activity and allograft inflammatory factor-1 overexpression.
    Albiero M; Rattazzi M; Menegazzo L; Boscaro E; Cappellari R; Pagnin E; Bertacco E; Poncina N; Dyar K; Ciciliot S; Iwabuchi K; Millioni R; Arrigoni G; Kraenkel N; Landmesser U; Agostini C; Avogaro A; Fadini GP
    Basic Res Cardiol; 2013 Jul; 108(4):368. PubMed ID: 23800875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endothelial progenitor cells are reduced in acromegalic patients and can be restored by treatment with somatostatin analogs.
    Fadini GP; Dassie F; Albiero M; Boscaro E; Albano I; Martini C; de Kreutzenberg SV; Agostini C; Avogaro A; Vettor R; Maffei P
    J Clin Endocrinol Metab; 2014 Dec; 99(12):E2549-56. PubMed ID: 25144634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating myeloid calcifying cells have antiangiogenic activity via thrombospondin-1 overexpression.
    Menegazzo L; Albiero M; Millioni R; Tolin S; Arrigoni G; Poncina N; Tessari P; Avogaro A; Fadini GP
    FASEB J; 2013 Nov; 27(11):4355-65. PubMed ID: 23901071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegvisomant: Balance after 10 years.
    Bernabeu I; Marazuela M
    Endocrinol Nutr; 2015 Oct; 62(8):363-5. PubMed ID: 26242927
    [No Abstract]   [Full Text] [Related]  

  • 7. Growth hormone isoforms in acromegalic patients before and after treatment with octreotide LAR.
    Lima GA; Wu Z; Silva CM; Barbosa FR; Dias JS; Schrank Y; Strasburger CJ; Gadelha MR
    Growth Horm IGF Res; 2010 Apr; 20(2):87-92. PubMed ID: 19884028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: a multicenter study.
    Filopanti M; Olgiati L; Mantovani G; Corbetta S; Arosio M; Gasco V; De Marinis L; Martini C; Bogazzi F; Cannavò S; Colao A; Ferone D; Arnaldi G; Pigliaru F; Peri A; Angeletti G; Jaffrain-Rea ML; Lania AG; Spada A
    J Clin Endocrinol Metab; 2012 Feb; 97(2):E165-72. PubMed ID: 22162472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New medical therapies of acromegaly.
    Maffezzoni F; Frara S; Doga M; Mazziotti G; Giustina A
    Growth Horm IGF Res; 2016; 30-31():58-63. PubMed ID: 27745780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.
    Tolis G; Angelopoulos NG; Katounda E; Rombopoulos G; Kaltzidou V; Kaltsas D; Protonotariou A; Lytras A
    Neuroendocrinology; 2006; 83(3-4):249-57. PubMed ID: 17047390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of action of octreotide in acromegalic tumours in vivo using dynamic contrast-enhanced magnetic resonance imaging.
    Sathyapalan T; Lowry M; Turnbull LW; Rowland-Hill C; Atkin SL
    Pituitary; 2007; 10(3):233-6. PubMed ID: 17541750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acromegaly.
    Scacchi M; Cavagnini F
    Pituitary; 2006; 9(4):297-303. PubMed ID: 17077948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Octreotide lar affects the volume of pituitary adenoma in acromegalic patients.
    Bałdys-Waligórska A; Krzentowska-Korek A; Gołkowski F; Sokołowski G; Hubalewska-Dydejczyk A
    Exp Clin Endocrinol Diabetes; 2011 May; 119(5):295-9. PubMed ID: 21264808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects.
    Gola M; Doga M; Bonadonna S; Mazziotti G; Vescovi PP; Giustina A
    Pituitary; 2006; 9(3):221-9. PubMed ID: 17036195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly.
    Colao A; Auriemma RS; Pivonello R
    Pituitary; 2016 Apr; 19(2):210-21. PubMed ID: 26290466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly.
    Gatto F; Feelders RA; van der Pas R; Kros JM; Waaijers M; Sprij-Mooij D; Neggers SJ; van der Lelij AJ; Minuto F; Lamberts SW; de Herder WW; Ferone D; Hofland LJ
    J Clin Endocrinol Metab; 2013 Jan; 98(1):E66-71. PubMed ID: 23118420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel use of endogenous GH-measurement directly after transsphenoidal microsurgery in acromegaly treated with pegvisomant.
    Lüdecke DK; Crock PA; Bidlingmaier M; Schuppert F
    Exp Clin Endocrinol Diabetes; 2013 Aug; 121(8):509-12. PubMed ID: 23765756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac risk in patients with treatment naïve, first-line medically controlled and first-line surgically cured acromegaly in comparison to matched data from the general population.
    Berg C; Petersenn S; Walensi M; Möhlenkamp S; Bauer M; Lehmann N; Roggenbuck U; Moebus S; Broecker-Preuss M; Sandalcioglu IE; Stolke D; Sure U; Joeckel KH; Erbel R; Führer D; Mann K;
    Exp Clin Endocrinol Diabetes; 2013 Feb; 121(2):125-32. PubMed ID: 23338744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Control of disease activity and tumor size after introduction of pegvisomant in a lanreotide-resistant acromegalic patient.
    Fendri S; Karaca P; Tiev E; Buchfelder M; Lalau JD
    Ann Endocrinol (Paris); 2013 Feb; 74(1):49-52. PubMed ID: 23337021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The association between treatment and systemic inflammation in acromegaly.
    Wolters TLC; van der Heijden CDCC; Pinzariu O; Hijmans-Kersten BTP; Jacobs C; Kaffa C; Hoischen A; Netea MG; Smit JWA; Thijssen DHJ; Georgescu CE; Riksen NP; Netea-Maier RT
    Growth Horm IGF Res; 2021; 57-58():101391. PubMed ID: 33964727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.